VotedBy VotedBy ⌕
Election Day · Tue, Nov 3See how your members of Congress voted →

H.R. 2871 · 115th Congress

Preserving Patient Access to Compounded Medications Act of 2017

Key: what the circles and colors mean

Each circle is a bill. The ring fills as it moves through Congress:

IntroducedPassed one chamberPassed both chambersBecame law (gold)Resolution agreed to (full, dark)Failed or vetoed (gray)

Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.

Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.

Never voted on. It didn't reach a floor vote before the 115th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.

HGR GriffithSponsor
62 cosponsors · 5 D, 57 R
HCD Cuellar CCR Collins TPR Poe BCR Carter FLR LoBiondo PSR Sessions PRR Roe MTR Thornberry ABR Biggs CMR McMorris Rodgers GHR Harper DYR Young PGR Gosar CPD Peterson DBR Brat NDR Dunn JBD Beatty BBR Babin CSR Stewart ABR Barr MCR Coffman DCR Collins BCR Comstock DLR LaHood POR Olson TRR Rokita SDR DesJarlais WJR Jones RWR Wittman KCR Cramer MMR McSally BGR Goodlatte FSR Sensenbrenner RBR Blum BGR Gibbs JLR Lewis RMR Marshall SPR Palazzo DYR Young SSR Stivers KCR Calvert STR Taylor SDR Duffy TMR MacArthur JDR Duncan FVD Vela GPR Palmer TBR Budd SKR King MAR Amodei JDR Duncan JHR Herrera Beutler CHR Higgins MJR Johnson EJR Jenkins JFR Fortenberry JAR Amash LGR Gohmert DND Norcross BLR Loudermilk JSR Shimkus RBR Bishop

1 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.

Preserving Patient Access to Compounded Medications Act of 2017

What it does: CRS summary · Introduced in House · Jun 12, 2017

Preserving Patient Access to Compounded Medications Act of 2017

This bill amends the Federal Food, Drug, and Cosmetic Act to expand the circumstances under which a drug may be compounded (manufactured at small scale) to allow pharmacists and physicians to compound drugs for administration to patients in an office or clinical setting, in accordance with state law. (Drugs that are compounded do not need to meet certain federal requirements regarding manufacturing, labeling, or approval.)

Dietary supplements may be used in the compounding of a drug.

The bill exempts from interstate distribution limits the dispensing of a compounded drug from the facility where it is compounded to a patient or health facility.

The scope of Food and Drug Administration (FDA) inspections of compounding pharmacies is limited to pertinent equipment, materials, containers, and labeling, which is the same scope as inspections of pharmacies. (Currently, the scope of inspections of compounding pharmacies is the same scope as inspections of drug manufacturers.)

The bill eliminates the requirement for compounding pharmacies to register with the FDA as drug manufacturers.

Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov

About this bill and sources

Official title: Preserving Patient Access to Compounded Medications Act of 2017

Latest action (Jun 16, 2017): Referred to the Subcommittee on Health.

Policy area: Health · Origin: House · Introduced: Jun 12, 2017

Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)

No recorded floor vote found.